<DOC>
	<DOCNO>NCT00349336</DOCNO>
	<brief_summary>This 2 arm study compare pharmacokinetics safety Avastin steady state 2 different dose regimen , combination XELOX ( oxaliplatin + Xeloda ) FOLFOX-4 ( oxaliplatin , leucovorin 5-fluorouracil ) . Patients randomize XELOX arm receive Avastin ( 7.5mg/kg iv ) Day 1 3 week cycle ; patient randomize FOLFOX-4 arm receive Avastin ( 5mg/kg iv ) Day 1 2 week cycle . The anticipated time study treatment 3-12 month , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Combination With XELOX FOLFOX-4 Patients With Metastatic Colorectal Cancer .</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>adult patient , &gt; =18 year age ; adenocarcinoma colon rectum , metastatic locally advanced disease ; &gt; =1 target lesion . patient previously receive systemic treatment advance metastatic disease ; patient receive adjuvant treatment nonmetastatic disease past 3 month ; previous therapy oxaliplatin Avastin .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
</DOC>